MedTrace Logo

Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)

NCT06965309 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-02-12

No results posted yet for this study

Summary

This is an investigator-initiated trial designed to evaluate the safety, and efficacy of HN2301 in refractory myasthenia gravis

Conditions

  • Refractory Myasthenia Gravis

Interventions

DRUG

HN2301 injection

Description: Three dose groups were set up, starting from the low dose group and climbing to explore the safe and effective dose.

Sponsors & Collaborators

  • Shanghai General Hospital (Songjiang Branch)

    collaborator UNKNOWN

  • Shenzhen MagicRNA Biotechnology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Ailian Du · Shanghai Songshan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-19
Primary Completion
2026-02-11
Completion
2026-02-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06965309 on ClinicalTrials.gov